Bayer May Pay Trius Up to $94 Million for Torezolid Antibiotic

Bayer AG (BAYN) agreed to pay Trius Therapeutics Inc. (TSRX) $25 million upfront for collaboration rights to the U.S. biotechnology company’s skin-infection antibiotic torezolid outside the U.S., Canada and Europe.

Bayer will contribute to global development costs for the experimental drug and may pay Trius as much as $69 million if the medicine meets certain development, regulatory and commercial goals, the Leverkusen, Germany-based company said in a statement today. Trius of San Diego, California, will also get double-digit royalties on net sales, Bayer said.

Torezolid is in the final phase of clinical development before U.S. and European Union regulatory approval and is expected to compete with Pfizer Inc.’s Zyvox.

To contact the reporter on this story: Naomi Kresge in Zurich at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.